Close Menu

NEW YORK – Danaher today reported a 4 percent year-over-year increase in its second quarter revenues, which included a 6 percent rise in life sciences segment revenues and a rise of almost 5 percent in its diagnostics segment.

For the three months ended June 28, total revenues reached $5.16 billion, up from $4.98 billion a year ago. It beat the consensus Wall Street estimate of $5.08 billion. Core revenue growth was about 6 percent, the Washington, DC-based conglomerate said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.